Different Doses of Neostigmine for Reversal of Moderate Neuromuscular Blockade in Children
Status:
Not yet recruiting
Trial end date:
2022-02-20
Target enrollment:
Participant gender:
Summary
There is no recent information on the required dose of neostigmine for the reversal of
cisatracurium-induced moderate neuromuscular blockade (NMB) [Train-of-four (TOF) count =
1-3)] in children. The aim of this study will be to evaluate by means of a prospective,
randomized and double-blinded clinical trial, the time required for reversal of moderate NMB
(TOFc 3) to T4/T1 (TOF ratio, TOFr) > 0.9 and TOFr = 1.0 after administration of different
doses of neostigmine (10, 20 or 30 mcg/kg) or placebo in children undergoing inhalational
(sevoflurane) general anesthesia. In addition, the probability of NMB reversal in less than
10 minutes, the presence of bradycardia, respiratory complications and postoperative vomiting
will be evaluated. The time for reversal is expected to be inversely proportional to the
administered dose of neostigmine.